Companies/Fennec Pharmaceuticals Inc.

Company profile

Fennec Pharmaceuticals Inc.

NASDAQ: FENC · Healthcare · Biotechnology

PublicHQ Research Triangle Park, NCCIK 0001211583Reports USD

#444 of 1,394 Healthcare companies by revenue34th-percentile growth

EA Score

61C

FH 67DQ 63GM 45SS 54

v0.1 · 65/100 weight · provisional

↑ disclosure history, 3-yr revenue growth · ↓ growth stability, revenue growth (YoY)

Methodology →

Revenue TTM

$51.0M

Rev growth YoY (TTM)

+65.0%

Net income (FY)

-$9.7M

Employees

Market cap

$305.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$44.6M$44.6M2025

Net income-$9.7M-$9.7M2025

Operating income-$6.3M-$6.3M2025

Total assets$70.6M$70.6M2025

Liabilities$35.1M$35.1M2025

Equity$35.5M$35.5M2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

$170.0k

FY21

$1.8M

FY23

$11.3M

FY23

$23.8M

FY23

$47.5M

FY24

$44.6M

FY25

Revenue by segment

Filed disclosures · FY2020

By product

Royalty100%

By geography

Not disclosed.

The read

Fennec Pharmaceuticals Inc. booked $44.6M in FY2025 revenue, contracting 6.1% year over year — slower than 66% of Healthcare companies we track, at a -21.8% net margin.

Peers · Healthcare

Organogenesis Holdings Inc.65B Carlsmed, Inc.43D Neumora Therapeutics, Inc. Common Stock——Palatin Technologies, Inc.41D

Key facts

CEOJeffrey S. Hackman

SectorHealthcare

IndustryBiotechnology

HeadquartersResearch Triangle Park, NC

ExchangeNASDAQ: FENC

Employees32

IPO date2017-09-15

Latest filings

8-K2026-06-10 8-K2026-05-22 8-K2026-05-18 10-Q2026-05-14 8-K2026-04-28 DEF 14A2026-04-28 8-K2026-04-22 8-K2026-04-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.